Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm currently has a $2.00 price target on the medical equipment provider’s stock. Zacks Investment Research‘s target price suggests a potential upside of 11.73% from the stock’s current price.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

CVRS has been the topic of a number of other reports. ValuEngine upgraded Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. B. Riley upgraded Corindus Vascular Robotics to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, March 22nd.

Shares of Corindus Vascular Robotics (CVRS) remained flat at $1.79 during mid-day trading on Tuesday. The company’s stock had a trading volume of 321,662 shares. Corindus Vascular Robotics has a 12-month low of $0.40 and a 12-month high of $2.25. The firm’s market cap is $334.87 million. The firm has a 50 day moving average price of $1.40 and a 200 day moving average price of $1.04.

Corindus Vascular Robotics (NYSEMKT:CVRS) last issued its earnings results on Tuesday, May 9th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. Corindus Vascular Robotics had a negative net margin of 1,272.20% and a negative return on equity of 181.63%. The business had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $1.59 million. Equities analysts predict that Corindus Vascular Robotics will post ($0.22) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/11/corindus-vascular-robotics-inc-cvrs-lifted-to-buy-at-zacks-investment-research.html.

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Corindus Vascular Robotics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 9,684 shares during the period. Schwab Charles Investment Management Inc. increased its position in Corindus Vascular Robotics by 240.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 201,900 shares during the period. Finally, Geode Capital Management LLC increased its position in Corindus Vascular Robotics by 73.3% in the first quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock worth $882,000 after buying an additional 284,855 shares during the period.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.